Challenges in Creating a Multidisciplinary Practice for Patients With NETs
October 20th 2017Bringing coordinated multidisciplinary cancer treatment together into one place is ideal to improve care for patients with neuroendocrine tumors (NETs), according to David C. Metz, MD, during the 10th Annual NANETS Symposium.
Read More
Dr. Metz on Somatostatin Analogs and Emerging Agents in NETs Landscape
October 19th 2017David C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).
Watch
NANETS Chair Explains How Symposium Addresses the Multidisciplinary Needs of Treating NETs
October 19th 2017David Metz, MD, chair of the North American Neuroendocrine Tumor Society, discusses the focus on multidisciplinary care and exciting areas of research being presented during the 10th Annual NANETS Symposium.
Read More
NETs Expert Looking Forward to New Research Updates, Networking at Upcoming NANETS Symposium
October 19th 2017As an experienced medical oncologist and clinical researcher specializing in the treatment of gastrointestinal tumors, Pamela Kunz, MD, says the upcoming 2017 North American Neuroendocrine Tumor Society (NANETS) Annual Symposium offers her a chance to not only expand her own knowledge of neuroendocrine tumor research, but also allows her to share her past experience with professionals just starting out in the field.
Read More
NANETS to Bring All Specialties in the NETs Community Together for 10th Annual Symposium
October 19th 2017The 2017 North American Neuroendocrine Tumor Society (NANETS) Annual Symposium is kicking off tomorrow, October 19, in Philadelphia with a 3-day lineup of presentations sure to leave professionals in the neuroendocrine community with a better understanding of ongoing neuroendocrine tumor research efforts, a look at what is on the horizon, and an abundance of networking opportunities with a variety of specialists throughout their field.
Read More
Three-Drug Regimen Active in BRAF-Mutant Melanoma
September 22nd 2017Triplet therapy for advanced, <em>BRAF</em> V600-mutant melanoma led to objective responses in 73% of a small group of patients enrolled in a phase I trial, according to updated results reported at the 2017 ESMO Annual Congress in Madrid.
Read More
Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC
September 20th 2017H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Watch
Study Identifies Subset of NSCLC Patients Who Experience Hyperprogression After Immunotherapy
September 19th 2017A multicenter retrospective analysis presented at the 2017 ESMO Congress found that a newly defined subset of patients treated with anti-PD-1/PD-L1 immunotherapy experienced accelerated tumor growth indicative of hyperprogressive disease (HPD).
Read More
Frontline Dabrafenib/Trametinib Combo Shows Promising Efficacy in BRAF+ NSCLC
September 19th 2017Frontline treatment with the combination of dabrafenib and trametinib induced an objective response rate of 64% (95% CI, 46%-79%) and a disease control rate of 75% in patients with <em>BRAF</em>-mutant metastatic non–small cell lung cancer.
Read More
Vx-001, a cancer vaccine that employs a new strategy targeting a universal tumor antigen, significantly improved overall survival in patients with advanced or metastatic non–small cell lung cancer who developed an immune response to the vaccine, according to findings presented at the 2017 ESMO Annual Congress in Madrid, Spain.
Read More
New Treatment Paradigm Required for Breast Cancer in Young Women
September 17th 2017Younger women with breast cancer, which make up of around 20% of patients, present with unique disease characteristics that warrant careful consideration of potentials treatments, particularly given the potential for long-term side effects.
Read More
Breast Cancer Genome to Shape Precision Medicine
September 16th 2017As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.
Read More
Determining the Risk Associated With Mutations Identified From Multigene Testing
September 16th 2017Figuring out how a certain genetic result found through multigene testing might change not only the type of intervention but its timing is the chief challenge, according to Mark Robson, MD, in a presentation at the 2017 Lynn Sage Breast Cancer Symposium.
Read More
Expert Sees Molecular Genetics Increasingly Integrated into Clinical Decision Making in MPNs
September 16th 2017Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.
Read More
Bosutinib Distinguishes Itself as Potential Option for Newly-Diagnosed CML
September 16th 2017Initial results from a phase III trial indicated that patients with newly diagnosed chronic myeloid leukemia treated with bosutinib (Bosulif) achieved response faster than patients treated with imatinib (Gleevec).
Read More
Combination Strategies With Ruxolitinib Explored in Myelofibrosis Treatment
September 15th 2017The treatment of myelofibrosis has changed significantly in the past few years, largely due to the approval of ruxolitinib (Jakafi). Although it provides durable improvements, the JAK inhibitor may be even more effective in combination—as inhibition of JAK-STAT signaling has not shown to be curative.
Read More
Challenges, Needs to Improve Treatment of Pediatric ALL
September 15th 2017Efforts to improve outcomes in pediatric acute lymphoblastic leukemia should follow leads provided by next-generation sequencing and appropriate use of minimal residual disease criteria, a pediatric hematologist said at the 2017 Society of Hematology Oncology Annual Meeting in Houston.
Read More
IBM's Watson a Potentially Valuable Partner for Oncologists, But Still a Work in Progress
September 15th 2017Andrew Seidman, MD, discusses the Watson for Oncology application and the potential for Watson to be a valuable partner for oncologists during the 19<sup>th</sup> Annual Lynn Sage Breast Cancer Symposium.
Read More
Finances and Disorganization Disrupt Global Breast Cancer Care
September 15th 2017Breast cancer is the most common cancer among women around the world, and those in low- and middle-income countries experience the most deaths from the disease, representing a major need for improvement with significant challenges.
Read More